Last checked at 11 Apr 2024 18:51
AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition
Policy approved with two-third of votes in favour
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News1
AZN Share
Chat
AZN Share
Trades
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,050.00
Bid:
12,038.00
Ask:
12,040.00
Change:
0.00 (0.00%)
Spread:
2.00 (0.017%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
12,050.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca gets positive breast cancer trial results; potassium drug suffers setback
Fri, 27th May 2016 07:32
(ShareCast News) - Phamaceuticals giant AstraZeneca announced positive results for its Faslodex drug for the treatment of metastatic breast cancer, but also said US regulators will not currently approve its new drug for high potassium levels because of a manufacturing issue.The company said on Friday that Faslodex met its primary endpoint of extended progression-free survival in post-menopausal women who have not had prior hormonal treatment for home-receptor-positive breast cancer. Sean Bohen, executive vice president of Global Medicines Development and chief medical officer at AstraZeneca, said: "The FALCON results bring us closer to offering more and earlier treatment options to postmenopausal women with HR+ locally-advanced or metastatic breast cancer; the potential to delay disease progression is important for these patients as there is currently no cure."Faslodex has over 10 years of clinical evidence and we are committed to exploring its potential along with the rest of our outstanding oncology portfolio"Also on Friday, AZN said the US Food & Drug Administration would not approve one of its new drugs because of a manufacturing problem.It said the FDA has issued a complete response letter (CRL) on the new drug application made for sodium zirconium cyclosilicate, the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by wholly-owned subsidiary ZS Pharma.The CRL refers to observations arising from a pre-approval manufacturing inspection. The FDA also acknowledged receipt of recently-submitted data which it has yet to review and said it does not require the generation of new clinical data."AstraZeneca and ZS Pharma are evaluating the content of the CRL and will work closely with the FDA to determine the appropriate next steps for the NDA."Societe Generale said the response from the FDA will probably delay launch by around six months to the second half of 2017."We spoke to AZN LN this morning. The group appears confident it can resolve these issues smoothly and swiftly. Our impression is that the FDA may be being overly vigilant. Nonetheless this news is unhelpful as ZS9 only entered AZN LN's pipeline in Q4 16 via the $3bn acquisition of ZS Pharma."Still, the bank said the news does not change its medium-term positive investment case on the stock, which it rates at 'buy'.At 0930 BST, AZN shares were down 0.3% to 3,998.50p.
More News
11 Apr 2024 17:13
FTSE 100 edges lower as financials drag
Lok'nStore surges to all-time high after buyout by Shurgard
*Read more11 Apr 2024 17:07
Banks weigh down Europe's STOXX 600 after ECB signals rate cuts
Outlook hike sends Ambu shares up
*Read more11 Apr 2024 15:56
London close: Stocks finish lower as ECB stands pat
(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.
Read more11 Apr 2024 11:50
LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision
(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.
Read more11 Apr 2024 08:56
TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023
(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.
Read more11 Apr 2024 08:54
LONDON MARKET OPEN: European markets mixed ahead of ECB decision
(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.
Read more11 Apr 2024 07:49
LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.
Read more11 Apr 2024 07:20
AstraZeneca to hike 2024 dividend by 7%
(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.
Read more8 Apr 2024 08:36
TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris
(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.
Read more8 Apr 2024 07:43
LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack
(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.
Read more8 Apr 2024 07:02
AstraZeneca's Enhurtu cancer gets US green light for adult patients
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.
Read more8 Apr 2024 06:53
TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.
Read more5 Apr 2024 09:42
AstraZeneca makes "breakthrough" in treating small cell lung cancer
(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.
Read more5 Apr 2024 07:50
LONDON BRIEFING: Shell to book USD600 million first-quarter write-off
(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.
Read more